


**An innovative, collaborative, and creative hub
to foster and accelerate the translation of
discoveries into tomorrow's healthcare solutions**





A dynamic Centre of Excellence for Commercialization and Research dedicated to drug discovery and development.

- Translation and commercialization of innovative projects emerging from academia and biotechnology companies aiming to respond to important medical needs
- Industry-level drug discovery and development expertise and an ability to help finance activities up to the stage of clinical proof-of-concept
- Project management according to industry standards
- Flexibility and virtual operational model where project activities are outsourced and conducted in the relevant contract research organizations (CROs) within the NEOMED Institute, the NEOMED Biologics and Vaccines Division, or elsewhere
- Projects to be out-licensed at predetermined development stage to pharma partners for further development or serve to start-up new companies around solid assets
- An existing portfolio of 10 projects from hit-identification to clinical proof-of-concept stages



An outstanding research and development facility acting as an open-access drug discovery hub, and offering a vibrant environment to nurture collaboration, innovation, and creativity.

- Modern building inherited from AstraZeneca, fully equipped for chemistry, biology, or drug metabolism studies, with a state-of-the-art vivarium; common spaces designed to favour communication and interaction
- Hosting 23 independent companies employing 175 people and offering services in medicinal chemistry, assay development, DMPK, Intellectual Property, and strategic recruitment consulting
- Exceptional platform for interactions between academia, biotechs, and industry for the benefits of patients and the entire biopharmaceutical community including investors, service firms, and governments
- Combining innovation and entrepreneurship-driven culture, the NEOMED Institute will continue to host companies operating predominantly in the development of small molecule therapeutics



A Centre of Excellence that will build on the scientific heritage of the GSK Laval site in vaccine and biologics development, and the innovative business model of the NEOMED Institute structured around three distinct and fully integrated pillars.

- The transformation of the GSK research facility, and its highly specialized laboratories and equipment, into a multi-tenant hub of small and medium-sized enterprises specialized in biologics and vaccines development
- The creation of a specialized contract research organization (CRO) that will offer clinical immunology and other biology services to the business community, and to GSK for at least three years
- The creation of a partnership between GSK and NEOMED in order to share risks and benefits on selected biologics and vaccine projects

GSK will invest \$47 million in the Centre of Excellence